RxDoctor Payments Data

John Dooley, MD

Internal Medicine · Washington, DCNPI 1467431155

Payments from drug & device makers

$878in general payments, 2019–2025

Across 40 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$230
  • Lilly USA, LLC$199
  • Pfizer$146
  • Novo Nordisk$87
  • Sumitomo Pharma America, Inc.$57
  • Idorsia Pharmaceuticals US Inc$34
  • plus $125 from 6 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$878 in reported general payments places this provider in the 75th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$189,977
Medicare patients
572
Services billed
5,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$139,278
MyrbetriqMirabegron40$34,118
OzempicSemaglutide22$29,872
JardianceEmpagliflozin14$25,281
XareltoRivaroxaban13$18,004
RybelsusSemaglutide11$16,320
Atorvastatin Calcium676$9,579
PradaxaDabigatran Etexilate Mesylate16$5,792
EdarbiAzilsartan Medoxomil14$5,211
PaxlovidNirmatrelvir/Ritonavir48$4,101
Galantamine ErGalantamine Hbr28$3,737
SynthroidLevothyroxine Sodium58$3,578
Rosuvastatin Calcium161$3,550
Tamsulosin Hcl115$2,891
Levothyroxine Sodium193$2,803

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$146$143,380193 claims
Novo NordiskOzempic, Rybelsus$87$46,19233 claims
Astellas Pharma US IncMyrbetriq$23$34,11840 claims
AbbVieSynthroid$15$3,57858 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →